Clinical trials: Extrahepatic Bile Duct Cancer, open to volunteers
Biliary Stricture, Bile Duct Cancer
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
Biliary stricture is mainly malignant in the adults and caused by several types of fatal malignancies such as pancreatic cancer, cholangiocarcinoma, and metastatic tumor, which have poor prognosis that the overall survival of…
- Conditions
- Biliary Stricture, Bile Duct Cancer, Pancreas Cancer
- Trial name
- ECCBILE (NCT06277531)
- Where
- 2 sites in China
- Volunteers
- 99 people
- Sponsor
- Peking University Third Hospital
Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma
- Trial name
- NCT06901622
- Testing
- Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Biliary Cancer, Bile Duct Cancer
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Background: Biliary tract carcinoma (BTC) is cancer of the slender tubes that carry fluids in the liver. People with advanced BTC have few treatment options, and their survival rates are very low.
- Conditions
- Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
- Trial name
- NCT05849480
- Testing
- oxaliplatin, capecitabine, Keytruda
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal or intrahepatic CCA with indication for bile duct…
- Trial name
- NCT06440993
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- 12 sites in Germany
- Volunteers
- 42 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Gastric/Gastroesophageal Junction Cancer, Breast Cancer
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors.
- Conditions
- Gastric/Gastroesophageal Junction Cancer, Breast Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT07036185
- Testing
- KJ015 Injection (Subcutaneous Injection)
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
Cholangiocarcinoma, Klatskin Tumor
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting.
- Conditions
- Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
- Trial name
- ACTICCA-2 (NCT06175845)
- Testing
- Intraductal biliary radiofrequency ablation
- Where
- 9 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Cholangiocarcinoma
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure…
- Trial name
- NCT05874414
- Testing
- GNS561 + Trametinib
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- Genfit
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
Biliary tract carcinoma (BTC), including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, ranks sixth in incidence among gastrointestinal malignancies and tenth in cancer-related mortality…
- Conditions
- Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma
- Trial name
- NCT07176962
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Yingbin Liu, MD, PhD, FACS
Pancreatic Cancer, Periampullary Cancer
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing…
- Conditions
- Pancreatic Cancer, Periampullary Cancer, Duodenal Cancer, Cholangiocarcinoma
- Trial name
- NBCA-MS (NCT07155525)
- Testing
- Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2), Standard(duct-to-mucosa) Pancreaticojejunostomy
- Where
- Egypt
- Volunteers
- 194 people
- Sponsor
- Minia University
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
This study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over…
- Trial name
- Beacon-BTC (NCT07265674)
- Testing
- Nanvuranlat, Physician's Best Choice
- Where
- 18 sites in United States
- Volunteers
- 480 people
- Sponsor
- J-Pharma Co., Ltd.
Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Bile Omics for Diagnosing Indeterminate Biliary Strictures
The diagnosis of malignant biliary strictures remains a challenging aspect of biliary endoscopy. Molecular biological testing techniques based on bile have been reported to improve detection rates.
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Strictures of Unknown Origin
- Trial name
- NCT07007832
- Testing
- Endoscopic retrograde cholangiopancreatography
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Bile Duct Cancer, Gall Bladder Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous…
- Conditions
- Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors
- Trial name
- NCT05000294
- Testing
- Atezolizumab, Tivozanib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Florida
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Pancreas Cancer, Pancreas Neoplasm
Prognostic Factors in Periampullary Tumors and Cysts
The project aims at analysing prognostic and predictive factors involved in diagnostics and surgical treatment of cysts and tumors in the pancreas and periampullary region using both clinical data and blood and tissue samples for…
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreas Cyst, Pancreatic Fistula
- Trial name
- NCT05155878
- Where
- Sweden
- Volunteers
- 500 people
- Sponsor
- Umeå University
Cholangiocarcinoma
A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma
This is a prospective, observational and exploratory clinical study. The object of this study is to evaluate the accuracy of a novel serological risk model on blood samples in early diagnosis of cholangiocarcinoma patients.
- Trial name
- NCT06658587
- Testing
- No interventions
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pancreatic Cancer, Advanced Biliary Cancer
Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer
This is a early Phase 1 open-label study to explore the safety and possible efficacy of EX02 CAR T cell therapy in the treatment of patients with unresectable and/or metastatic pancreatic/bile duct cancer.
- Trial name
- NCT06196658
- Testing
- anti-EX02 CAR T cells
- Volunteers
- 6 people
- Sponsor
- Zhang Xiaofeng,MD
Small Bowel Cancer, Colorectal Cancer
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective.
- Conditions
- Small Bowel Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer
- Trial name
- LIVELONG (NCT06101277)
- Testing
- Ablative local therapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, Davis